BMS-986464

BMS-986464 is the active metabolite of BMS-986465, a small molecule drug originally under investigation by Bristol Myers Squibb. Its development focused on evaluating safety, tolerability, absorption, food effect, and pharmacokinetics in healthy volunteers. While BMS-986465 is described as a tyrosine-protein kinase 2 (TYK2) inhibitor, the exact mechanism for BMS-986464 is inferred to be the same, functioning as the moiety responsible for biological activity after conversion from the prodrug. Clinical testing was aimed at central nervous system/neuroinflammatory indications but was terminated at an early phase, and no active trials are ongoing[1][2][3][5][7][9].